Large Scale, Historical Controlled Study Finds CAD Increases Sensitivity in
Cancer Detection with Only a Small Increase in Recall Rate
BEDFORD, Mass., Feb. 13 /PRNewswire-FirstCall/ -- Hologic, Inc. (Nasdaq: HOLX), a diversified medical technologies company specializing in imaging systems, diagnostics, and interventional devices dedicated to serving the healthcare needs of women, today announced the publication of a large scale breast screening trial comparing a single radiologist using computer- aided detection (CAD) to double reading without CAD. The author of the study is Dr. Matthew Gromet of the Breast Imaging Section of Charlotte Radiology, a large imaging practice (approximately 66,000 screening mammograms a year) in Charlotte, North Carolina. The study(1), published in the on-line version of the American Journal of Roentgenology, the scientific journal of the American Roentgen Ray Society, will appear in the April 2008 issue of the research journal. The study compared the recall rate, sensitivity, positive predictive value, and cancer detection rate for single reading with CAD, versus double reading without CAD. Biopsy and pathology data for positive cases were also compared.
Dr. Gromet found that a single reader with CAD had a statistically significant increase in sensitivity (11%) and a smaller increase in recall rate (4%), when compared a single reader without CAD assistance. He also found that single reading with CAD review, when compared with independent double reading, resulted in a not statistically significant increase in sensitivity but with a statistically significant lower recall rate. With manpower constraints limiting the use of double reading, Dr. Gromet concludes that "CAD appears to be an effective alternative that provides similar, and potentially greater, benefits."
The results were based on the performance of nine radiologists at Charlotte Radiology with a mean level of experience in mammography of 15 years. The mammograms in the study were screen-film studies obtained on Hologic mammography equipment. The CAD technology used in the study was the Hologic R2 ImageChecker(R) CAD system. A total of 231,221 exams were included in the study; 49% of the exams were double read without CAD and 51% were single read with CAD.
"The Gromet study is a valuable addition to the body of knowledge on
the performance of radiologists reading screening mammograms with CAD
assistance," says Ronald A. Castellino, MD, FACR, Chief Medical Officer for
Hologic. "A strength of this study is the large number of malignancies as
well as the large number of cases in both arms of the study (double reading
without CAD vs. single reading with CAD). The number of CAD cases is nearly
four times greater than that reported in the Fenton paper(2) published in
the New England Journal of Medicine last year. An additional strength is
the use of data from the same pool of experienced radiologists with
considerable CAD experience."
A copy of this study may be found at: http://www.ajronline.org/aheadofprint/04_07_2812_WI.pdf
Note on Sensitivity, Double Reading and CAD
The efficacy of screening mammography is enhanced when sensitivity is high and the recall rate is low. Double reading, though used by few practices in the United States, is a method for increasing sensitivity commonly used in European screening programs. CAD has become increasingly popular as an alternative way to increase sensitivity, since double reading is time- consuming and because of a shortage of radiologists.
CAD has the potential to increase sensitivity of screening mammography by marking areas of interest that might otherwise be overlooked by interpreting radiologists. However, CAD also may place false marks, identifying areas of suspicion that are not cancer. A small fraction of false marks may result in unnecessary patient recalls for further evaluation. The major goal for CAD is to reduce oversights when screening mammograms are read; the radiologist is still responsible for lesion analysis and final interpretation of an examination.
About Hologic, Inc.
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women. Hologic's core business units are focused on breast health, diagnostics, GYN surgical, and skeletal health. Hologic provides a comprehensive suite of technologies with products for mammography and breast biopsy, radiation treatment for early-stage breast cancer, cervical cancer screening, treatment for menorrhagia, osteoporosis assessment, preterm birth risk assessment, and mini C-arm for extremity imaging. For more information visit http://www.hologic.com.
Forward Looking Disclaimer
This News Release contains forward-looking information that involves
risks and uncertainties, including statements about the effect of the use
of Computed-Aided Detection, or CAD, technology (as utilized in Hologic's
R2 ImageChecker CAD system) in mammography screening. There can be no
assurance that the effects demonstrated in the study described herein will
be replicated in any particular manner with respect to an individual
patient as the actual effect of the use of CAD technology in mammography
screenings can only be determined on a case-by-case basis depending on the
particular circumstances of the exam and patient in question. Hologic
expressly disclaims any obligation or undertaking to release publicly any
updates or revisions to the data or statements presented herein to reflect
any change in Hologic's expectations or any change in events, conditions or
circumstances on which any such data or statements is based. Certain
factors that could adversely affect Hologic's business and prospects are
described in Hologic's filings with the Securities and Exchange Commission.
(1) M. Gromet, "Comparison of Computer-Aided Detection to Double Reading
of Screening Mammograms: Review of 231,221 Mammograms," AJR 2008;
(2) J. Fenton, et al. "Influence of Computer-Aided Detection on
Performance of Screening Mammography," New England Journal of
Glenn Muir Frances Doria
Executive Vice President and CFO Director, Investor Relations
Hologic, Inc. Hologic, Inc.
Tel: 781.999.7300 Tel: 781.999.7377
|SOURCE Hologic, Inc.|
Copyright©2008 PR Newswire.
All rights reserved